Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer
NCT06152523Phase 2Withdrawn
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2023
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of monalizumab and volrustomig in carcinoma, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Dose-Limiting Toxicities at 3 years and Objective Response Rate at 24 weeks. Planned start Dec 2023; status: withdrawn.
02
Drugs
monalizumabvolrustomig
03
Conditions
carcinoma
Beyond the preview
Go deeper on NCT06152523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06152523.